Evidence map›Paper›PMID 41368246›Full record

ArticleTranslational andrology and urology2025

Machine learning studies for predicting 5-year renal cell cancer survival: a multicenter study.

Mingchao Wang, Yiming Ding, Zhenwei Zhou, Yuanlei Chen, Zeyi Lu

Abstract read
In one paragraph

Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mingchao Wang *Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yiming Ding *Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zhenwei ZhouDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yuanlei ChenDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zeyi LuDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Renal cell carcinoma (RCC) is biologically heterogeneous, complicating prognosis and treatment. Our study aims to clarify prognostic factors and support evidence-based clinical decision-making in RCC management. Methods: This study analyzed clinical data of RCC patients diagnosed between 2010 and 2021 from the Surveillance, Epidemiology, and End Results database. Prognostic factors associated with patient outcomes were selected using least absolute shrinkage and selection operator regression and Boruta. Seven machine learning algorithms were employed to construct predictive models for 5-year survival in RCC patients. Shapley Additive Explanations (SHAP) analysis was utilized to visually interpret the model's predictions. Model performance was evaluated using the following metrics: accuracy, sensitivity, specificity, positive predictive value, negative predictive value, F1 score, area under the receiver operating characteristic curve (AUC), Brier score, and estimated calibration index (ECI). Results: In the realm of predicting 5-year survival for RCC patients, the gradient boosting machine (GBM) model achieved the best overall performance with an AUC of 0.841 [95% confidence interval (CI): 0.833-0.850], along with the lowest Brier score (0.127; 95% CI: 0.126-0.128) and ECI (0.005; 95% CI: 0.003-0.007). Furthermore, SHAP analysis highlighted key clinical factors influencing 5-year survival of RCC patients, reinforcing their prognostic significance in RCC. Conclusions: This study developed an accurate predictive model for 5-year survival in RCC patients using machine learning, which may offer valuable support to clinicians in making informed clinical decisions.

Indexed as

5-year survivalMachine learningrenal cell cancerSurveillance, Epidemiology, and End Results Program (SEER)

Identifiers

PMID41368246
PMCPMC12683448

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.